Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

38.00
+0.19000.50%
Post-market: 38.000.00000.00%18:37 EDT
Volume:1.19M
Turnover:45.93M
Market Cap:4.50B
PE:-7.22
High:39.73
Open:38.60
Low:37.90
Close:37.81
Loading ...

Q4 2024 Cytokinetics Inc Earnings Call

Thomson Reuters StreetEvents
·
01 Mar

Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb

Cytokinetics’ Mixed Outlook: Hold Rating Amid Execution Challenges and Modest Trial Impact

TIPRANKS
·
28 Feb

Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses

GuruFocus.com
·
28 Feb

Cytokinetics’ Promising Pipeline and Strategic Expansion Drive Buy Rating

TIPRANKS
·
28 Feb

Cytokinetics Files For Mixed Shelf - SEC Filing

Reuters
·
28 Feb

Cytokinetics files automatic mixed securities shelf

TIPRANKS
·
28 Feb

Cytokinetics Inc: Sales Agreement Prospectus Supplement Covering Offering of up to $500.0 Mln of Common Stock

THOMSON REUTERS
·
28 Feb

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
28 Feb

Cytokinetics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Cytokinetics: Q4 Earnings Snapshot

Associated Press Finance
·
28 Feb

Cytokinetics Q4 Net Loss Narrows, Revenue Rises

MT Newswires Live
·
28 Feb

Cytokinetics Q4 2024 GAAP EPS $(1.26) Misses $(1.17) Estimate, Sales $16.927M Beat $1.742M Estimate

Benzinga
·
28 Feb

BRIEF-Cytokinetics Q4 Basic EPS USD -1.26

Reuters
·
28 Feb

Cytokinetics Q4 Operating Expenses USD 155.967 Million

THOMSON REUTERS
·
28 Feb

Cytokinetics Q4 Basic EPS USD -1.26

THOMSON REUTERS
·
28 Feb

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire
·
28 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Feb

Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey
·
24 Feb

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
20 Feb